• Capricor Therapeutics recently reported positive long-term data for its Duchenne muscular dystrophy cell therapy Deramiocel and disclosed that an FDA advisory committee will review its Biologics License Application on July 29, 2026.
• At the same time, Capricor was removed from several Russell indexes, highlighting a contrast between encouraging clinical and regulatory progress and reduced index inclusion.
• We’ll now examine how the upcoming FDA advisory committee review for Deramiocel reshapes Capricor’s investment narrative and risk profile.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Capricor Therapeutics Investment Narrative Recap

To own Capricor today, you essentially have to believe Deramiocel can become an approved treatment for Duchenne muscular dystrophy and eventually support a viable commercial business, despite Capricor’s lack of current revenue and ongoing losses. The upcoming FDA advisory committee meeting on July 29, 2026 is now the clear near term catalyst, while the biggest risk remains any adverse regulatory outcome or further delay. The recent removal from Russell indexes does not materially change that core risk reward picture.

Among the recent announcements, the five year HOPE 2 open label extension data is especially important, because it backs up HOPE 3’s Phase 3 results with longer term functional and cardiac outcomes. For many shareholders, this kind of durability and safety profile is central to the thesis that Deramiocel could ultimately support meaningful, sustained revenue if approved. How the FDA advisory committee interprets this package of data will be central to Capricor’s next chapter and...

Capricor Therapeutics’ narrative projects $245.5 million revenue and $109.6 million earnings by 2029.

Uncover how Capricor Therapeutics' forecasts yield a $54.67 fair value, a 144% upside to its current price.

Exploring Other Perspectives

In contrast, the most pessimistic analysts were assuming only about US$114.5 million of revenue and US$32.5 million of earnings by 2029, reminding you that some see delayed approval and dilution risk as far more material, and that both bullish and bearish views may shift once the advisory committee decision and long term data are fully absorbed.

Explore 5 other fair value estimates on Capricor Therapeutics - why the stock might be worth just $39.40!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Capricor Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Capricor Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Capricor Therapeutics' overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 41 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.